5-草酰壬基色胺 | 157798-13-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 5-草酰壬基色胺
• 英文名称: 5-(Nonyloxy)tryptamine oxalate
• 英文别名: 3-(2-aminoethyl)-5-nonyloxyindole oxalate；5-Nonyloxytryptamine oxalate；2-(5-nonoxy-1H-indol-3-yl)ethanamine;oxalic acid
• CAS: 157798-13-5
• 化学式: C₂H₂O₄*C₁₉H₃₀N₂O
• 分子量: 392.495
• InChiKey: JORSCLBFSAAOFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.95
• 重原子数：
  28
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• 5-HYDROXYTRYPTAMINE 1B RECEPTOR-STIMULATING AGENT FOR USE AS A PROMOTER OF SATELLITE CELLS SELF-RENEWAL AND/OR DIFFERENTIATION
  申请人：Institut Pasteur

  公开号：EP3799873A1

  公开（公告）日：2021-04-07

  The present invention relates to the field of muscle regeneration, and more particularly to the replenishment of the in vivo muscle stem cells pool. It more specifically relates to a 5-hydroxytryptamine B1 receptor-stimulating agent, and to a composition comprising said agent, for use as i) a promoter of satellite cells self-renewal and/or differentiation, and/or ii) an agent preventing and/or inhibiting the satellite cells pool exhaustion. The invention further encompasses therapeutic and screening methods.

  本发明涉及肌肉再生领域，特别是体内肌肉干细胞池的补充。本发明更具体地涉及一种5-羟色胺B1受体刺激剂，以及一种包含上述刺激剂的组合物，可用作i）卫星细胞自我更新和/或分化的促进剂，和/或ii）防止和/或抑制卫星细胞池耗竭的药物。本发明还包括治疗和筛选方法。
• USE OF ANTIDEPRESSANT AGENTS FOR TREATING THE COVID-19 DISEASE
  申请人：ASSISTANCE PUBLIQUE, HOPITAUX DE PARIS

  公开号：EP3928775A1

  公开（公告）日：2021-12-29

  The present invention relates to the therapeutic uses of antidepressant compounds such as SSRIs, SNRIs and a2-antagonist antidepressants for lowering the risk of death and/or intubation in patient suffering from a viral infection caused by at least one betacoronavirus, in particular by the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).

  本发明涉及抗抑郁剂化合物的治疗用途，如 SSRIs、SNRIs 和 a2-拮抗剂抗抑郁剂，用于降低由至少一种 betacoronavirus（特别是 SARS-CoV-2（严重急性呼吸系统综合征冠状病毒 2））引起的病毒感染患者的死亡和/或插管风险。
• 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
  申请人：INSTITUT PASTEUR

  公开号：US11013830B2

  公开（公告）日：2021-05-25

  The present invention relates to the field of regenerative medicine, and more particularly to the improvement of the in vivo engraftment potential of biological material to be administered to a subject in need thereof.

  本发明涉及再生医学领域，更具体地说，是关于如何提高生物材料的体内移植潜能，供需要的受试者使用。
• 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
  申请人：INSTITUT PASTEUR

  公开号：US11344515B2

  公开（公告）日：2022-05-31

  The present invention relates to the field of muscle regeneration, and more particularly to the replenishment of the in vivo muscle stem cells pool. It more specifically relates to a 5-hydroxytryptamine B1 receptor-stimulating agent, and to a composition comprising said agent, for use as i) a promoter of satellite cells self-renewal and/or differentiation, and/or ii) an agent preventing and/or inhibiting the satellite cells pool exhaustion. The invention further encompasses therapeutic and screening methods.

  本发明涉及肌肉再生领域，特别是体内肌肉干细胞池的补充。本发明更具体地涉及一种5-羟色胺B1受体刺激剂，以及一种包含上述刺激剂的组合物，可用作i）卫星细胞自我更新和/或分化的促进剂，和/或ii）防止和/或抑制卫星细胞池耗竭的药物。本发明还包括治疗和筛选方法。
• Serotonergic compositions and methods for treatment of mild cognitive impairment
  申请人：——

  公开号：US20020173511A1

  公开（公告）日：2002-11-21

  A method of treating Mild Cognitive Impairment has been discovered. The treatment method comprises administering an effective amount of a serotonergic agent, including, but not limited to dexnorfenfluramine. The agent can be any serotonergic agonist, partial agonist, serotonin reuptake inhibitor, or combinations of these agents. The treatment method also encompasses combinations of serotonergic agents and non-steroidal anti-inflammatory agents. The treatment method may also delay the onset of Mild Cognitive Impairment, dementia, or both.

  现已发现一种治疗轻度认知障碍的方法。该治疗方法包括施用有效量的血清素能制剂，包括但不限于右诺芬氟拉明。该药物可以是任何血清素能激动剂、部分激动剂、血清素再摄取抑制剂或这些药物的组合。治疗方法还包括血清素能药物和非甾体抗炎药物的组合。治疗方法还可以延缓轻度认知功能障碍、痴呆或两者的发生。